This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n9http://linked.opendata.cz/resource/drugbank/drug/DB05009/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB05009/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB05009/identifier/pubchem-substance/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05009/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05009
rdf:type
n3:Drug
n3:description
BMS068645 is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. It is developed by Bristol-Myers Squibb and is in phase II of clinical trials.
n3:generalReferences
# Cerqueira MD: Advances in pharmacologic agents in imaging: new A2A receptor agonists. Curr Cardiol Rep. 2006 Mar;8(2):119-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16524538
n3:group
investigational
n3:indication
Investigated for use/treatment in cardiovascular disorders and inflammatory disorders (unspecified).
owl:sameAs
n6:DB05009
dcterms:title
BMS068645
adms:identifier
n9:4958252 n10:10560395 n11:DB05009 n12:6456013
n3:mechanismOfAction
BMS068645 is designed to selectively stimulate the A2a adenosine receptor responsible for coronary vasodilation. Research to date suggests that this compound could potentially reduce or eliminate side effects associated with currently available pharmacologic stress agents that are not selective for the A2a adenosine receptor.
n3:IUPAC-Name
n4:271B6240-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6246-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6245-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6242-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6243-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6244-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B623E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B623F-363D-11E5-9242-09173F13E4C5 n4:271B623C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B623D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B624C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B624D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6247-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6248-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B624A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6249-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B624B-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
250386-15-3
n3:Bioavailability
n4:271B6252-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6254-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6255-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6251-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6250-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6253-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6241-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B624E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B624F-363D-11E5-9242-09173F13E4C5